Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 1/2016

01.02.2016 | Management of Heart Failure (T Meyer, Section Editor)

Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction

verfasst von: Abhishek Jaiswal, Astha Chichra, Vinh Q. Nguyen, Taraka V. Gadiraju, Thierry H. Le Jemtel

Erschienen in: Current Heart Failure Reports | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Chronic obstructive pulmonary disease (COPD) and heart failure with reduced ejection fraction (HFrEF) commonly coexist in clinical practice. The prevalence of COPD among HFrEF patients ranges from 20 to 32 %. On the other hand; HFrEF is prevalent in more than 20 % of COPD patients. With an aging population, the number of patients with coexisting COPD and HFrEF is on rise. Coexisting COPD and HFrEF presents a unique diagnostic and therapeutic clinical conundrum. Common symptoms shared by both conditions mask the early referral and detection of the other. Beta blockers (BB), angiotensin-converting enzyme inhibitors, and aldosterone antagonists have been shown to reduce hospitalizations, morbidity, and mortality in HFrEF while long-acting inhaled bronchodilators (beta-2-agonists and anticholinergics) and corticosteroids have been endorsed for COPD treatment. The opposing pharmacotherapy of BBs and beta-2-agonists highlight the conflict in prescribing BBs in COPD and beta-2-agonists in HFrEF. This has resulted in underutilization of evidence-based therapy for HFrEF in COPD patients owing to fear of adverse effects. This review aims to provide an update and current perspective on diagnostic and therapeutic management of patients with coexisting COPD and HFrEF.
Literatur
1.
de Miguel Díez J, Morgan JC, García RJ. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:305.PubMedCentralCrossRefPubMed
2.
Macchia A et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012;39(1):51–8.CrossRefPubMed
3.
Hawkins NM et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail. 2010;12(1):17–24.CrossRefPubMed
4.
Kwon BJ et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail. 2010;12(12):1339–44.CrossRefPubMed
5.
Agarwal SK et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail. 2012;14(4):414–22.PubMedCentralCrossRefPubMed
6.
Marin JM et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med. 2010;182(3):325–31.CrossRefPubMed
7.
Gosker HR et al. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. CHEST J. 2003;123(5):1416–24.CrossRef
8.
Rutten FH et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887–94.CrossRefPubMed
9.
Schunemann HJ et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. CHEST J. 2000;118(3):656–64.CrossRef
10.
Sin DD, Man SP. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol. 2005;83(1):8–13.CrossRefPubMed
11.
McGarvey LP et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62(5):411–5.PubMedCentralCrossRefPubMed
12.
Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49(2):171–80.CrossRefPubMed
13.
Davie A et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312(7025):222.PubMedCentralCrossRefPubMed
14.
Chhabra S.K. and M. Gupta Coexistent chronic obstructive pulmonary disease-heart failure: mechanisms; diagnostic and therapeutic dilemmas. 2010.
15.
Hawkins NM et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–9.PubMedCentralCrossRefPubMed
16.
Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. J Thorac Dis. 2012;4(3):310.PubMedCentralPubMed
17.
Dimopoulou I et al. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med. 1998;92(12):1321–5.CrossRefPubMed
18.
Sirak TES. Jelic and T.H. Le Jemtel Therapeutic update: non-selective beta-and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2004;44(3):497–502.CrossRefPubMed
19.
Mascarenhas J et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J. 2008;155(3):521–5.CrossRefPubMed
20.
Güder G et al. The impact of heart failure on the classification of COPD severity. J Card Fail. 2012;18(8):637–44.CrossRefPubMed
21.
Matera MG, Martuscelli E, Cazzola M. Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther. 2010;23(1):1–8.CrossRefPubMed
22.
Rusinaru D et al. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol. 2008;101(3):353–8.CrossRefPubMed
23.
O’Kelly N et al. Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. World J Cardiol. 2012;4(3):66.PubMedCentralCrossRefPubMed
24.
Kotlyar E et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. The J Heart Lung Transplant. 2002;21(12):1290–5.CrossRefPubMed
25.
Salpeter S et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med. 2003;97(10):1094–101.CrossRefPubMed
26.
Shelton RJ et al. Effect of a community heart failure clinic on uptake of β blockers by patients with obstructive airways disease and heart failure. Heart. 2006;92(3):331–6.PubMedCentralCrossRefPubMed
27.
Salpeter S.S. et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002(2): Cd003566.
28.
Staszewsky L et al. Clinical; neurohormonal; and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail. 2007;13(10):797–804.CrossRefPubMed
29.
van Gestel YR et al. Impact of cardioselective β-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008;178(7):695–700.CrossRefPubMed
30.
Puente-Maestu L et al. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir Med. 2014;108(5):737–44.CrossRefPubMed
31.
Sin DD, Man SP. A curious case of β-blockers in chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):849–50.CrossRefPubMed
32.
Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease: a time-dependent analysis. Am J Respir Crit Care Med. 2013;187(7):715–20.CrossRefPubMed
33.
Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart. 2000;84(6):615–9.PubMedCentralCrossRefPubMed
34.
Jabbour A et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780–7.CrossRefPubMed
35.
Lainscak M et al. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105:S44–9.CrossRefPubMed
36.
Mentz RJ et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013;111(4):582–7.CrossRefPubMed
37.
Maffei A. and G. Lembo, Nitric oxide mechanisms of nebivolol. Therapeutic Advances in Cardiovascular Disease; 2009.
38.
Rutten FH et al. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–7.CrossRefPubMed
39.
Etminan M et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmon Med. 2012;12(1):48.CrossRef
40.
So PP-S et al. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol. 2012;109(10):1504–9.CrossRefPubMed
41.
Frances S, Handoko ML. β-blockers in pulmonary arterial hypertension: evolving concepts of right heart failure. Eur Respir J. 2015;46(3):619–21.CrossRef
42.
Bandyopadhyay D. et al. Outcomes of β-blocker use in pulmonary arterial hypertension: a propensity-matched analysis. European Respiratory Journal. 2015: p. ERJ-02155-2014.
43.
Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339(8):489–97.CrossRefPubMed
44.
Chen J et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001;37(7):1950–6.CrossRefPubMed
45.
McMurray JJ et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.CrossRefPubMed
46.
Tavazzi L et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013;170(2):182–8.CrossRefPubMed
47.
Bartziokas K et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulmon Pharmacol Ther. 2011;24(5):625–31.CrossRef
48.
Mancini GB et al. Reduction of morbidity and mortality by statins; angiotensin-converting enzyme inhibitors; and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–60.CrossRefPubMed
49.
Mortensen EM et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10(45):1465–9921.
50.
Mentz RJ et al. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. J Card Fail. 2012;18(7):515–23.CrossRefPubMed
51.
Coirault C et al. Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure. CHEST J. 2001;119(6):1755–60.CrossRef
52.
53.
Calverley PM, Rennard SI. What have we learned from large drug treatment trials in COPD? Lancet. 2007;370(9589):774–85.CrossRefPubMed
54.
Au DH et al. Association between chronic heart failure and inhaled β-2-adrenoceptor agonists. Am Heart J. 2004;148(5):915–20.CrossRefPubMed
55.
Ng TM et al. Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol. 2002;40(1):140–5.CrossRefPubMed
56.
Hawkins NM et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol. 2011;57(21):2127–38.CrossRefPubMed
57.
Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium—the FDA’s conclusions. N Engl J Med. 2010;363(12):1097–9.CrossRefPubMed
58.
Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. CHEST J. 2004;125(2):669–82.CrossRef
59.
Minasian AG et al. Bronchodilator responsiveness in patients with chronic heart failure. Heart Lung: J Acute Critical Care. 2013;42(3):208–14.CrossRef
60.
Ashrafian H, Violaris AG. Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint. Prim Care Respir J. 2005;14(5):236–41.CrossRefPubMed
61.
Sin DD et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(7):760–5.CrossRefPubMed
62.
Souverein P et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart. 2004;90(8):859–65.PubMedCentralCrossRefPubMed
63.
White WB et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. CHEST J. 2013;144(3):758–65.CrossRef
64.
McCullough PA et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B‐type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10(3):198–204.CrossRefPubMed
65.
Fisher K et al. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure. Chest. 2015;147:637–45.CrossRefPubMed
66.
COPD G. Global Strategy for the Diagnosis; Management and Prevention Chronic Obstructive Pulmonary Disease. 2013.
67.
Chang CL et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–8.CrossRefPubMed
68.
Ellis KL et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail. 2013;15(10):1138–47.CrossRefPubMed
69.
Stefan M.S. et al. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease; heart failure or hypertension. Thorax; 2012: p. thoraxjnl-2012-201945.
70.
Dransfield MT et al. Use of β blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63(4):301–5.CrossRefPubMed
71.
Zhang J et al. Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2012;17(4):715–20.CrossRefPubMed
72.
Singer AJ et al. Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease. Ann Emerg Med. 2008;51(1):25–34.CrossRefPubMed
73.
74.
Beghé B et al. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J. 2013;41(4):993–5.CrossRefPubMed
Metadaten
Titel
Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction
verfasst von
Abhishek Jaiswal
Astha Chichra
Vinh Q. Nguyen
Taraka V. Gadiraju
Thierry H. Le Jemtel
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 1/2016
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-016-0278-8

Weitere Artikel der Ausgabe 1/2016

Current Heart Failure Reports 1/2016 Zur Ausgabe

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (A Hasan, Section Editor)

Patient Selection for Long-Term Mechanical Circulatory Support: Is It Ever too Early for the NYHA Class III Patient?

Prevention of Heart Failure (M S J Sutton, Section Editor)

MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure

Pharmacologic Therapy (W H W Tang, Section Editor)

The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction

Comorbidities of Heart Failure (C Angermann, Section Editor)

Comorbidities in Heart Failure: Are There Gender Differences?

Pharmacologic Therapy (W H W Tang, Section Editor)

Ivabradine in Management of Heart Failure: a Critical Appraisal

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (A Hasan, Section Editor)

Complex Care Options for Patients With Advanced Heart Failure Approaching End of Life

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen